UCB BIOSCIENCES, Inc. clinical trials

Acquired by UCB S.A.

The registry lists 50 studies whose lead sponsor is UCB BIOSCIENCES, Inc.. 2 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 15, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 50. All UCB S.A. studies →

• A Phase 3 Study of Fenfluramine Hydrochloride in Rett SyndromeRecruitingNCT07503444Phase 3

  Sponsor listed in the registry: UCB BIOSCIENCES, Inc. · UCB BIOSCIENCES, Inc. — acquired company within the UCB S.A. group

• Doxecitine and Doxribtimine-Expanded AccessAvailableNCT06590493

  Sponsor listed in the registry: UCB BIOSCIENCES, Inc. · UCB BIOSCIENCES, Inc. — acquired company within the UCB S.A. group

• Pediatric Arthritis Study of Certolizumab PegolCompletedNCT01550003Phase 3

  Sponsor listed in the registry: UCB BIOSCIENCES GmbH · UCB BIOSCIENCES GmbH — acquired company within the UCB S.A. group

• A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Fenfluramine (Hydrochloride) in Infants 1 Year to Less Than 2 Years of Age With Dravet SyndromeCompletedNCT06118255Phase 3

  Sponsor listed in the registry: UCB BIOSCIENCES, Inc. · UCB BIOSCIENCES, Inc. — acquired company within the UCB S.A. group

• An Open-Label Study of Continuation Treatment With Combination Pyrimidine Nucleosides in Patients With TK2 DeficiencyCompletedNCT03845712Phase 2

  Sponsor listed in the registry: UCB BIOSCIENCES, Inc. · UCB BIOSCIENCES, Inc. — acquired company within the UCB S.A. group

• A Study to Assess Drug-drug Interaction of ZX008 in Healthy Male and Female Study ParticipantsCompletedNCT06679413Phase 1

  Sponsor listed in the registry: UCB BIOSCIENCES, Inc. · UCB BIOSCIENCES, Inc. — acquired company within the UCB S.A. group

• Safety and Efficacy of Lacosamide as Additional Therapy in Patients Suffering From Epileptic Tonic-Clonic SeizuresCompletedNCT02408549Phase 3

  Sponsor listed in the registry: UCB BIOSCIENCES, Inc. · UCB BIOSCIENCES, Inc. — acquired company within the UCB S.A. group

• SECURE, the Cimzia ® Crohn's Disease Post-Marketing RegistryCompletedNCT00844285

  Sponsor listed in the registry: UCB BIOSCIENCES, Inc. · UCB BIOSCIENCES, Inc. — acquired company within the UCB S.A. group

• Study to Investigate Safety and Tolerability of Intravenous Lacosamide in Children.CompletedNCT02710890Phase 2/3

  Sponsor listed in the registry: UCB BIOSCIENCES, Inc. · UCB BIOSCIENCES, Inc. — acquired company within the UCB S.A. group

• A Clinical Study to Investigate the Efficacy and Safety of Lacosamide as an Add on Therapy in Children With Epilepsy With Partial-onset SeizuresCompletedNCT01964560Phase 3

  Sponsor listed in the registry: UCB BIOSCIENCES, Inc. · UCB BIOSCIENCES, Inc. — acquired company within the UCB S.A. group

• Multicenter Study Evaluating Certolizumab Pegol Compared to Placebo in Subjects With axSpA Without X-ray Evidence of ASCompletedNCT02552212Phase 3

  Sponsor listed in the registry: UCB BIOSCIENCES GmbH · UCB BIOSCIENCES GmbH — acquired company within the UCB S.A. group

• The Long-term Safety and Efficacy of CDP6038 (Olokizumab) With Active Rheumatoid ArthritisTerminatedNCT01533714Phase 2

  Sponsor listed in the registry: UCB BIOSCIENCES, Inc. · UCB BIOSCIENCES, Inc. — acquired company within the UCB S.A. group

• Open-label Study to Assess the Safety and Efficacy of CDP6038 (Olokizumab) in Patients Who Completed RA0056TerminatedNCT01296711Phase 2

  Sponsor listed in the registry: UCB BIOSCIENCES, Inc. · UCB BIOSCIENCES, Inc. — acquired company within the UCB S.A. group

• An Open-Label Study to Determine Safety , Tolerability, and Efficacy of Oral Lacosamide in Children With EpilepsyCompletedNCT00938912Phase 2

  Sponsor listed in the registry: UCB BIOSCIENCES, Inc. · UCB BIOSCIENCES, Inc. — acquired company within the UCB S.A. group

• Brivaracetam Safety and Efficacy Follow-up Study in Subjects With EpilepsyCompletedNCT01339559Phase 3

  Sponsor listed in the registry: UCB BIOSCIENCES, Inc. · UCB BIOSCIENCES, Inc. — acquired company within the UCB S.A. group

• Efficacy and Safety of Lacosamide as Adjunctive Therapy in Subjects ≥1 Month to <4 Years With Partial-onset SeizuresCompletedNCT02477839Phase 3

  Sponsor listed in the registry: UCB BIOSCIENCES, Inc. · UCB BIOSCIENCES, Inc. — acquired company within the UCB S.A. group

• UCB Cimzia Pregnancy Follow-up StudyTerminatedNCT02775656

  Sponsor listed in the registry: UCB BIOSCIENCES, Inc. · UCB BIOSCIENCES, Inc. — acquired company within the UCB S.A. group

• Trial Comparing the Efficacy and Safety of Lacosamide (LCM) to Carbamazepine Controlled-Release (CBZ-CR); Initial Monotherapy in Epilepsy; Subjects Aged 16 and OlderCompletedNCT01243177Phase 3

  Sponsor listed in the registry: UCB BIOSCIENCES GmbH · UCB BIOSCIENCES GmbH — acquired company within the UCB S.A. group

• A Study to Assess the Safety and Efficacy of Lacosamide Versus Placebo (a Pill Without Active Medication) in Patients With Idiopathic Generalised Epilepsy Who Are Already Taking Anti-epileptic MedicationsCompletedNCT02408523Phase 3

  Sponsor listed in the registry: UCB BIOSCIENCES, Inc. · UCB BIOSCIENCES, Inc. — acquired company within the UCB S.A. group

• Study to Evaluate Maintenance of Sustained Remission of axSpA With CZP Compared to PlaceboCompletedNCT02505542Phase 3

  Sponsor listed in the registry: UCB BIOSCIENCES GmbH · UCB BIOSCIENCES GmbH — acquired company within the UCB S.A. group

• Study of Lacosamide as an Adjunctive Drug Treatment for Epilepsy in Patients With Brain TumorsCompletedNCT02276053

  Sponsor listed in the registry: UCB BIOSCIENCES GmbH · UCB BIOSCIENCES GmbH — acquired company within the UCB S.A. group

• A Multicener, Postmarketing Study Evaluating the Transfer of Cimzia From the Mother to the Infant Via the PlacentaCompletedNCT02019602Phase 1

  Sponsor listed in the registry: UCB BIOSCIENCES, Inc. · UCB BIOSCIENCES, Inc. — acquired company within the UCB S.A. group

• Trial to Evaluate The Efficacy Of Rotigotine on Parkinson's Disease-Associated Motor Symptoms And ApathyCompletedNCT01782222Phase 4

  Sponsor listed in the registry: UCB BIOSCIENCES GmbH · UCB BIOSCIENCES GmbH — acquired company within the UCB S.A. group

• A Study to Evaluate Safety of Long Term Therapy of Certolizumab Pegol Patients With Crohn's DiseaseCompletedNCT00552344Phase 3

  Sponsor listed in the registry: UCB BIOSCIENCES GmbH · UCB BIOSCIENCES GmbH — acquired company within the UCB S.A. group

• Certolizumab Pegol in Subjects With Active Axial SpondyloarthritisCompletedNCT01087762Phase 3

  Sponsor listed in the registry: UCB BIOSCIENCES GmbH · UCB BIOSCIENCES GmbH — acquired company within the UCB S.A. group

• Certolizumab Pegol in Subjects With Adult Onset Active and Progressive Psoriatic ArthritisCompletedNCT01087788Phase 3

  Sponsor listed in the registry: UCB BIOSCIENCES GmbH · UCB BIOSCIENCES GmbH — acquired company within the UCB S.A. group

• Trial to Demonstrate the Efficacy and Safety of Conversion to Lacosamide Monotherapy for Partial-onset SeizuresCompletedNCT00520741Phase 3

  Sponsor listed in the registry: UCB BIOSCIENCES, Inc. · UCB BIOSCIENCES, Inc. — acquired company within the UCB S.A. group

• Evaluating Long Term Safety of Lacosamide (LCM) to Carbamazepine Controlled-release (CBZ-CR); Initial Monotherapy in Epilepsy Subjects 16 Years and OlderCompletedNCT01465997Phase 3

  Sponsor listed in the registry: UCB BIOSCIENCES GmbH · UCB BIOSCIENCES GmbH — acquired company within the UCB S.A. group

• Determine Safety and Efficacy of Long-term Oral Lacosamide in Patients With Partial SeizuresCompletedNCT00522275Phase 3

  Sponsor listed in the registry: UCB BIOSCIENCES, Inc. · UCB BIOSCIENCES, Inc. — acquired company within the UCB S.A. group

• Open-Label Extension Study to Assess the Safety and Seizure Frequency Associated With Lacosamide for Primary Generalized Tonic-Clonic Seizures in Subjects With EpilepsyCompletedNCT01118962Phase 2

  Sponsor listed in the registry: UCB BIOSCIENCES, Inc. · UCB BIOSCIENCES, Inc. — acquired company within the UCB S.A. group

• Study to Assess the Long-term Safety of Oral Lacosamide in Subjects With Partial-onset SeizuresCompletedNCT00655486Phase 3

  Sponsor listed in the registry: UCB BIOSCIENCES, Inc. · UCB BIOSCIENCES, Inc. — acquired company within the UCB S.A. group

• Open-Label Study to Assess Lacosamide Safety as Add-on Therapy for Primary Generalized Tonic-Clonic Seizures in Subjects With EpilepsyCompletedNCT01118949Phase 2

  Sponsor listed in the registry: UCB BIOSCIENCES, Inc. · UCB BIOSCIENCES, Inc. — acquired company within the UCB S.A. group

• Safety of Intravenous Lacosamide Dose Followed by Twice Daily Oral Lacosamide in Subjects With Partial-onset SeizuresCompletedNCT00655551Phase 3

  Sponsor listed in the registry: UCB BIOSCIENCES, Inc. · UCB BIOSCIENCES, Inc. — acquired company within the UCB S.A. group

• Efficacy Evaluation of Intravenous Brivaracetam and Phenytoin in Subjects With Nonconvulsive Electrographic SeizuresTerminatedNCT02088957Phase 2

  Sponsor listed in the registry: UCB BIOSCIENCES, Inc. · UCB BIOSCIENCES, Inc. — acquired company within the UCB S.A. group

• Alprostadil in Peripheral Arterial Occlusive Disease (PAOD) Stage IVCompletedNCT00596752Phase 4

  Sponsor listed in the registry: UCB BIOSCIENCES GmbH · UCB BIOSCIENCES GmbH — acquired company within the UCB S.A. group

• Dose Escalating Study of Rotigotine in Pediatric Subjects With Restless Legs SyndromeCompletedNCT01495793Phase 2

  Sponsor listed in the registry: UCB BIOSCIENCES, Inc. · UCB BIOSCIENCES, Inc. — acquired company within the UCB S.A. group

• A Multicenter, Postmarketing Study Evaluating the Concentration of Cimzia® in Mature Breast Milk of Lactating MothersCompletedNCT02154425Phase 1

  Sponsor listed in the registry: UCB BIOSCIENCES, Inc. · UCB BIOSCIENCES, Inc. — acquired company within the UCB S.A. group

• Long-Term Follow-Up Study for Safety, Efficacy and Tolerability of Rotigotine in Adolescents With Restless Legs SyndromeCompletedNCT01498120Phase 2

  Sponsor listed in the registry: UCB BIOSCIENCES, Inc. · UCB BIOSCIENCES, Inc. — acquired company within the UCB S.A. group

• Open-label, Bioequivalence Study of Certolizumab Pegol 200 mg Solution Injected Either by a Prefilled Syringe (Reference) or by an E-Device (Test) in Healthy SubjectsCompletedNCT02806219Phase 1

  Sponsor listed in the registry: UCB BIOSCIENCES, Inc. · UCB BIOSCIENCES, Inc. — acquired company within the UCB S.A. group

• A Study to Compare the Adhesiveness of 2 Different Rotigotine Patches Used for the Treatment of Parkinson's DiseaseCompletedNCT02230904Phase 1

  Sponsor listed in the registry: UCB BIOSCIENCES GmbH · UCB BIOSCIENCES GmbH — acquired company within the UCB S.A. group

• Study Evaluating the Pharmacokinetics of Keppra Extended Release (XR) in Children and Adults With EpilepsyCompletedNCT00961441Phase 2

  Sponsor listed in the registry: UCB BIOSCIENCES, Inc. · UCB BIOSCIENCES, Inc. — acquired company within the UCB S.A. group

• Study to Evaluate the Efficacy of Rotigotine on Parkinson's Disease-Associated PainCompletedNCT01744496Phase 4

  Sponsor listed in the registry: UCB BIOSCIENCES GmbH · UCB BIOSCIENCES GmbH — acquired company within the UCB S.A. group

• A Sleep Laboratory Study to Investigate the Safety and Efficacy of the Rotigotine Skin Patch in Subjects With Restless Legs Syndrome and End-Stage Renal Disease Requiring HemodialysisCompletedNCT01537042Phase 3

  Sponsor listed in the registry: UCB BIOSCIENCES GmbH · UCB BIOSCIENCES GmbH — acquired company within the UCB S.A. group

• Study to Evaluate the Pharmacokinetics (PK), Safety, Tolerability of Single-Dose Transdermal Rotigotine in Japanese and Caucasian Healthy Male / Female SubjectsCompletedNCT01761526Phase 1

  Sponsor listed in the registry: UCB BIOSCIENCES GmbH · UCB BIOSCIENCES GmbH — acquired company within the UCB S.A. group

• Study to Evaluate the Pharmacokinetics, Safety, Tolerability of Repeated Dose Transdermal Rotigotine in Japanese and Caucasian SubjectsCompletedNCT01854216Phase 1

  Sponsor listed in the registry: UCB BIOSCIENCES GmbH · UCB BIOSCIENCES GmbH — acquired company within the UCB S.A. group

• Study to Evaluate the Pharmacokinetics, Safety, Tolerability of Single Dose Lacosamide in Subjects With Renal Impairment Compared to Healthy SubjectsCompletedNCT01796938Phase 1

  Sponsor listed in the registry: UCB BIOSCIENCES GmbH · UCB BIOSCIENCES GmbH — acquired company within the UCB S.A. group

• A Phase 3b, Open-Label, Safety and Efficacy Study of Rotigotine as Add-On Therapy With Low Doses of Pramipexole or Ropinirole in Patients With Advanced Parkinson's DiseaseCompletedNCT01723904Phase 3

  Sponsor listed in the registry: UCB BIOSCIENCES GmbH · UCB BIOSCIENCES GmbH — acquired company within the UCB S.A. group

• A Phase 4, Open-label Study to Assess the Feasibility and Efficacy on Motor and Non-motor Symptoms of Switching From Pramipexole or Ropinirole to Rotigotine Transdermal Patch in Subjects With Advanced Idiopathic Parkinson's DiseaseCompletedNCT01711866Phase 4

  Sponsor listed in the registry: UCB BIOSCIENCES GmbH · UCB BIOSCIENCES GmbH — acquired company within the UCB S.A. group

• Effects of Neupro on Cardiovascular Observations in Patients With Restless Legs SyndromeCompletedNCT01455012Phase 4

  Sponsor listed in the registry: UCB BIOSCIENCES GmbH · UCB BIOSCIENCES GmbH — acquired company within the UCB S.A. group

• A Phase II Study to Assess the Efficacy and Safety of Olokizumab in Patients With Crohn's DiseaseWithdrawnNCT01635621Phase 2

  Sponsor listed in the registry: UCB BIOSCIENCES GmbH · UCB BIOSCIENCES GmbH — acquired company within the UCB S.A. group